Document is current
Any future updates will be listed below
-
Authors
Yagi, Tomoko https://orcid.org/0000-0003-4749-8267
Ozone, Motohiro
Ioji, Tetsuya
Murotani, Kenta
Nishi, Akinori
Uchimura, Naohisa
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 13 December 2025
First Online: 9 February 2026
Declarations
:
: Tomoko Yagi has provided central scoring and received personal fees from Idorsia Pharmaceuticals Ltd., and provided consulting services and received personal fees from Nxera Pharma Japan Co., Ltd., and received speaker’s bureau fees from Shionogi and Co., Ltd. Motohiro Ozone has received research/grants from Eisai Co., Ltd.; and speakers bureau fees from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Tsumura and Co., Sumitomo Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd., Teijin Pharma Ltd., Mochida Pharmaceutical Co., Ltd., Shionogi and Co., Ltd., Daiichi Sankyo Co., Ltd., and Taisho Pharmaceutical Holdings Co., Ltd. received speaker’s honoraria from Eisai Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., and Tsumura and Co., Shionogi and Co., Mochida Pharmaceutical Co. Tetsuya Ioji declares no conflict of interest. Kenta Murotani declares no conflict of interest. Akinori Nishi declares no conflict of interest. Naohisa Uchimura has received speaker’s honoraria from Eisai Co., Ltd., MSD K.K. Takeda Pharmaceutical Co., Ltd., Shionogi and Co., Mochida Pharmaceutical Co.
: Not applicable. This study involved secondary analysis of previously collected and de-identified data. All participants provided written informed consent for the original clinical trial, which included consent for future research use of anonymized data.
